Study of visual outcome and complications of iris-claw intraocular lens implantation to correct aphakia

Abstract

Aim: To study the visual outcome and complications of irisclaw intraocular lens implantation to correct aphakia. Objectives: To study the visual outcome in patients with irisclaw lens implantation. To document the various complications associated with irisclaw lens implantation. To evaluate the safety of irisclaw lens implantation. Materials and Methods: Patient's eyes with no capsular support that had iris claw intraocular lens to correct aphakia between 2016 to 2018. Results: The study comprises of 50 eyes of 50 patients who underwent iris claw intraocular lens implantation to correct aphakia with no posterior capsular support. In our study population, the maximum number (70%) of patients had the preoperative BCVA of logMAR 0.18, ranging 0.18–0.78, with a mean of 0.28 ± 0.18, At 6month postoperative followup, of the total patients, 4% had the BCVA of log MAR 0.78, 2% had the BCVA of logMAR 0.6, maximum 88% had the BCVA of logMAR 0.18, and 6% had the BCVA of logMAR 0.3. In the early postoperative complications, 22% of patients had raised IOP, which was controlled on a shortterm antiglaucoma drug (timolol e/d bd); 12% of patients had pupil distortion; and 12% had corneal edema, which subsides on subsequent followup. 6% of patients had anterior chamber reaction and hyphema. Conclusion: Irisclaw lens implantation gives the good visual outcome in the patients of cataract with inadequate capsular support. The anatomical position of IOL is well maintained by the technique. Minor complications were treatable with no visionthreatening complication. Few patients had the late postoperative complication, which needs to be minimized. The technique is easy to master, generally safe, and effective on shortterm followup.